Abstract:We have proposed a new class of PPARγ Agonist containing 2H‐pyran‐2‐ones and thieno[3,2‐c]pyran‐2‐ones as the core nucleus. These compounds were synthesized under mild conditions from ketene dithioacetal. The molecular docking and dynamics of these compounds show that three compounds 10 e, 10 f, and 10 h exhibit the best result and binding interactions. Peroxisome proliferator‐activated receptor gamma (PPAR‐γ) is a well‐known member of the PPAR family and a potential target for the treatment of various disorders. Herein, we present the design and synthesis of various 6‐aryl‐4‐sec.amino‐2‐oxo‐2H‐pyran‐3‐carbonitrile derivatives and functionalized thieno[3,2‐c]pyran‐2‐ones, derived from ketene dithioacetal. Then all the synthesized compounds were docked for their activity as PPAR‐γ to predict the binding mechanism and affinities regarding rosiglitazone and muraglitazar. Our studies revealed that three compounds 10 e, 10 f, and 10 h showed significant binding affinities, with energy ranges comparable to standard drugs rosiglitazone and muraglitazar. The docking conformation studies revealed that the selected compounds nicely interact with PPAR‐γ in the ligand binding domain with positive predictive values. We also performed molecular dynamics of the most potent compounds to validate the result. Our results indicate that these novel compounds are potential PPAR‐γ ligands, offering new possibilities for therapeutic applications. This study underscores the potential of these synthesized compounds in the development of novel PPAR‐γ agonists.

Design,synthesis and bioactivity of 4-[(5-methyl-2-aryloxazol-4-yl) methoxy]benzylene(benzyl)-heterocyclic compounds

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Synthesis and biological activity of novel 1,3,4-oxadiazole derivatives containing a pyrazole moiety

Design, Synthesis and Evaluation of PPAR Gamma Binding Activity of 2-Thioxo-4-thiazolidinone Derivatives

Design, Synthesis and Hypoglycemic Activity of 3-Methyl-1-phenyl-4-{4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]benzylene(benzyl)}-2-pyrazol-5-one

Design, Synthesis And Hypoglycemic Activity Of 3-Methyl-1-Phenyl-4-{4-[(5-Methyl-2-Phenyloxazol-4-Yl)Methoxy] Benzylene(Benzyl)}-2-Pyrazol-5-One

Design,synthesis and biological activities of 1-(5- t -butyl-2-benzoxazolemethyl)-4-aryloxyalkyl-piperazine as α1 adrenoceptor antagonists

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety

Design, Synthesis, and Evaluation of Novel L-Phenylglycine Derivatives As Potential PPARγ Lead Compounds

Design, Synthesis and Biological Activity of Novel Substituted Phenyl Oxazol Based Compounds

Synthesis And Preliminary Evaluation Of Antidiabetic Activity Of 4-(1-Aryl-3-Aryl/Arylalkyl-3-Oxopropylamino)-N-(5-Methyl-3-Isoxazolyl)Be Nzene Sulfonamide

Design, Synthesis and PPAR Activities of 5-Arylmethylene and 5-Heteroaromatic Methylene Thiazolidine-2,4-diones

Synthesis and Activities of Natural Product 4-O-β-d-glucopyranosyl-benzoxazolin-2(3h)-one and Derivatives of 4-Substituted Benzoxazolone

Design, Synthesis and Antidiabetic Activities of 5-Arylmethylene Thiazolidine-2,4-dione Derivatives

Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ

Synthesis and Biological Evaluation of Various New Bis-Isoxazoline Derivatives As Potential Antioxidant Additives

Synthesis and Biological Activity of 1-(1,4-benzodioxan-2-yl-carbonyl)-4-aryloxy-alkyl-piperazine As Α_1-Adrenoceptor Antagonists

Design, Synthesis and Computational Insight of Isolated and Thiophene fused 2H‐Pyran‐2‐ones as PPAR‐γ Agonist

Synthesis, biological evaluation and 3D-QSAR study of 1-(1,4-benzodioxan-2-ylcaronyl)-4-aryloxyalkyl-piperazines as α1-adrenoceptor antagonists

Design and Synthesis of 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy}phenyl)propanoic Acid: A Novel Triple-acting PPARα, -Γ, and -Δ Agonist